InterSystems Launches HealthShare AI Assistant to Optimize Data Retrieval and Clinical Engagement with Conversational Intelligence
InterSystems, a creative data technology provider powering more than 1 billion health records worldwide, today announced the launch of InterSystems HealthShare AI Assistant, a new generative AI capability designed to assist clinicians, case managers, and administrators in accessing and understanding patient information faster and more intuitively.
Built on the trusted foundation of InterSystems HealthShare Unified Care Record (UCR), HealthShare AI Assistant introduces a conversational interface that enables users to securely query, summarize, and navigate complex longitudinal health records using natural language prompts. The AI Assistant queries records from thousands of diverse clinical data sources and leverages Generative AI to surface relevant insights and present information using industry-standard displays—empowering users with faster, more intuitive access to comprehensive patient data and key insights.
Some key capabilities of HealthShare AI Assistant include:
- Conversational Chat Interface - Empowers users to ask clinical questions or request patient summaries in plain language, delivering concise, context-aware insights instantly.
- Pre-Built and Custom Prompts - Provides clinically curated starter prompts and enables organizations to build tailored, role-based configurations.
- Source Traceability - Connects every AI-generated response to its verified record source, promoting transparency and clinical trust.
- Seamless Integration - Operates within the HealthShare Clinical Viewer and Navigation Application keeping the assistant embedded in the user's natural workflow.
- Comprehensive Governance - Implements configurable data profiles, role-based access controls, and full audit tracking to support safe, responsible AI use.
“AI in healthcare must be grounded in trust, interoperability, and reliable data,” said Don Woodlock, head of global healthcare solutions at InterSystems. “With HealthShare AI Assistant, we’re giving healthcare professionals a faster and safer way to access the information they need, right from within their existing workflows. It’s about reducing cognitive burden, improving efficiency, and letting clinicians focus on caring for patients.”
HealthShare AI Assistant pilot programs have demonstrated meaningful gains in efficiency and user satisfaction. A usability study run with Healthix, one of the largest public health information exchanges in the United States, showed that the AI Assistant quantitatively improved clinician workflow, reduced time spent reviewing records, and surfaced useful and actionable insights.
“Collecting information from 9,000+ facilities for over 21 million patients comes with an abundance of data,” said Todd Rogow, CEO at Healthix. “With HealthShare AI Assistant, our clinician users now have a tool to get an instant, clinically validated summary drawn from years of records, delivering a holistic view of a patient's medical history at time of care.”
HealthShare AI Assistant is part of the broader InterSystems HealthShare suite, which powers data interoperability and connected care across more than 80 countries. The new AI capability is available immediately to HealthShare users in supported regions.
For more information, visit www.InterSystems.com/HealthShare.
About InterSystems
InterSystems, a creative data technology provider, delivers a unified foundation for next-generation applications for healthcare, finance, manufacturing, and supply chain customers in more than 80 countries. Our data platforms solve interoperability, speed, and scalability problems for large organizations around the globe to unlock the power of data and allow people to perceive data in imaginative ways. Established in 1978, InterSystems is committed to excellence through its 24×7 support for customers and partners around the world. Privately held and headquartered in Boston, Massachusetts, InterSystems has 38 offices in 28 countries worldwide. For more information, please visit InterSystems.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251112864064/en/
Contacts
InterSystems PR Contact:
Zach Keating
pr@intersystems.com
617.551.5158
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mindbreeze Named a Leader in the IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 Vendor Assessment12.11.2025 19:01:00 EET | Press release
Mindbreeze, a leading global provider of AI-based knowledge management solutions, has been named a Leader in the IDC MarketScape: Worldwide General-Purpose Knowledge Discovery Software 2025 Vendor Assessment (doc #US53011225, November 2025). In the IDC MarketScape 14 vendors of knowledge discovery software were evaluated. For the assessment, IDC divided potential key measures for success into two primary categories: capabilities and strategies. Get your complimentary copy of the excerpt here. The IDC MarketScape notes, “Companies looking for reliable, context-aware insights from internal and external sources should consider Mindbreeze. The platform enables decision making for compliance, risk management, and strategic planning, appealing to business areas such as customer service, finance, legal, and HR. It can tailor pre-built search applications to specific departments for search while supporting broader knowledge management and digital workspace initiatives.” "We are proud to be rec
Ardian Set to Mobilize Development Finance Institutions (DFIs) With European Investment Bank (EIB), Proparco and British International Investment (BII) for a €100m Commitment for Its Nature-Based Solutions Strategy12.11.2025 18:12:00 EET | Press release
Ardian, a world-leading private investment firm, today announces that it has secured commitment from several Development Finance Institutions (DFIs), the European Investment Bank (EIB) and Proparco. British International Investment (BII) have signaled their intention to provide commitment to the Nature Based Solutions fund. Total fund commitments will stand for a total of c. €100m by year end to Ardian’s Nature-Based Solutions (NBS) strategy. As anchor investors, EIB’s development arm EIB Global commits €50m, while Proparco will commit €20m and British International Investment has received approval for a €10m commitment, subject to final negotiations. Averrhoa NBS is a SFDR1 Article 9 impact fund overseen by Ardian’s Infrastructure team in partnership with aDryada, a specialist developer and manager of large-scale ecosystem restoration projects. The strategy is dedicated to investing in projects to reforest and restore wetlands and mangroves, intended to protect biodiversity while enab
ViTAA Medical Secures FDA 510(k) Clearance for AiORTA™ Plan — Marking the First Step in Its Hyper-Precise Aortic Care Platform12.11.2025 17:00:00 EET | Press release
ViTAA Medical Solutions Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for AiORTA™ Plan, the company’s fully automated, hyper-precise aortic surgery planning solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112394413/en/ This clearance represents a key milestone in the evolution of ViTAA’s broader AiORTA™ platform, built to support physicians across the full continuum of aortic care. ViTAA’s additional innovations—AiORTA™ Maps and AiORTA™ Watch—are currently in multicenter clinical studies, progressing rapidly toward future clinical release. A Leap Forward in Aortic Surgery Planning Built to automate key preoperative measurements and streamline aortic case prep, AiORTA™ Plan generates a complete aortic plan in minutes. The zero-footprint, web-based system performs automated aneurysm segmentation, centerline extraction, precise diameter and angulation measurements
Andersen Consulting Collaborates with TruScore12.11.2025 16:30:00 EET | Press release
Andersen Consulting announces a Collaboration Agreement with TruScore, enhancing its human capital offering to help clients build stronger leadership teams and organizational cultures. Headquartered in the U.S., TruScore specializes in delivering fully customized survey hosting solutions that empower organizations to run scalable, secure, white-label assessment programs tailored to their unique needs. Providing bespoke 360-degree feedback solutions, TruScore works with Fortune 500 corporations, leadership development companies, and independent coaches to design and manage their own proprietary assessment experiences. “In today’s dynamic business environment, organizations need more than just strategy—they need strong, resilient leadership to execute that strategy successfully,” said Derek Murphy, CEO of TruScore. “Through this collaboration with Andersen Consulting, we can bring our assessment and development expertise to a broader audience, helping clients identify and cultivate the l
Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 202512.11.2025 16:30:00 EET | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that data from multiple pipeline programs, including long-term and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option, will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112742665/en/ “We are excited about the breadth of data we’re presenting at CTOS this year, which underscore the strong progress we continue to sustain across our pipeline,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “We look forward to sharing encore data from our Phase 3 MOTION study of vimseltinib and providing updates on our DCC-3009 Phase 1 program, which demonstrate how we can expand our GIST treatment capabilities by t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom